PBPH is designed to track the performance of the 10 largest global pharmaceutical companies. The ETF achieves this by holding a concentrated portfolio of leading firms in the pharmaceutical sector. As of 2026-03-15, its top holdings include Eli Lilly and Co (13.85%), Johnson & Johnson (9.35%), and AbbVie Inc (6.33%). The fund offers investors a targeted approach to investing in the global pharmaceutical industry, focusing on established, large-cap companies. This strategy differentiates PBPH from broader healthcare ETFs that may include a wider range of companies across various healthcare sub-sectors. PBPH's investment strategy is suitable for investors seeking concentrated exposure to the pharmaceutical industry's largest players. Past performance does not guarantee future results.
PBPH (PBPH) ETF Analysis
PBPH offers focused exposure to the 10 largest global pharmaceutical companies. The fund's concentrated portfolio includes pharmaceutical giants like Eli Lilly and Johnson & Johnson, providing targeted access to the global pharmaceutical sector. With a 0.00% dividend yield and a beta of 0.00, PBPH may appeal to investors seeking capital appreciation within the pharmaceutical industry. As of 2026-03-15, potential investors should analyze PBPH's concentrated holdings and sector-specific risks before investing. Past performance does not guarantee future results.
PBPH (PBPH) ETF — Price, Holdings & Analysis
PBPH offers focused exposure to the 10 largest global pharmaceutical companies. The fund's concentrated portfolio includes pharmaceutical giants like Eli Lilly and Johnson & Johnson, providing targeted access to the global pharmaceutical sector. With a 0.00% dividend yield and a beta of 0.00, PBPH may appeal to investors seeking capital appreciation within the pharmaceutical industry. As of 2026-03-15, potential investors should analyze PBPH's concentrated holdings and sector-specific risks before investing. Past performance does not guarantee future results.
ETF Overview
Risk Metrics
PBPH's concentrated portfolio of only 10 holdings introduces significant concentration risk. A substantial portion of the fund's assets is allocated to its top holdings, such as Eli Lilly and Johnson & Johnson, meaning the fund's performance is highly dependent on the performance of these few companies. The fund's sector focus on pharmaceuticals also exposes it to sector-specific risks, including regulatory changes, patent expirations, and drug pricing pressures. With a beta of 0.00, PBPH has historically shown very low volatility relative to the broader market. Investors should carefully consider their risk tolerance and investment objectives before investing in PBPH, given its concentrated nature and sector-specific risks. Past performance does not guarantee future results.
Top Holdings
- Eli Lilly and Co (LLY): 13.85%
- Johnson & Johnson (JNJ): 9.35%
- AbbVie Inc (ABBV): 6.33%
- Novartis AG Registered Shares (NOVN.SW): 5.32%
- Roche Holding AG (ROG.SW): 5.27%
- Merck & Co Inc (MRK): 4.89%
- AstraZeneca PLC (AZN.L): 4.83%
- Amgen Inc (AMGN): 4.56%
- Gilead Sciences Inc (GILD): 3.98%
- Pfizer Inc (PFE): 3.42%
Dividend Yield
0.00%
Risk Metrics
- Beta: 0.00
常见问题
What is PBPH and what does it track?
PBPH is an exchange-traded fund that aims to provide investors with targeted exposure to the largest global pharmaceutical companies. The fund achieves this by tracking an index composed of the 10 largest companies in the global pharmaceutical sector. As of 2026-03-15, PBPH's top holdings include Eli Lilly and Co, Johnson & Johnson, and AbbVie Inc. This concentrated approach allows investors to focus specifically on the performance of leading pharmaceutical firms, rather than a broader healthcare market.
What is the expense ratio for PBPH?
While the expense ratio for PBPH is not explicitly provided in the given data, it's important for potential investors to consider the costs associated with owning an ETF. Expense ratios represent the annual cost of operating the fund, expressed as a percentage of the fund's assets. Investors should compare PBPH's expense ratio to similar ETFs in the pharmaceutical or healthcare sectors to assess its cost-effectiveness. Lower expense ratios generally benefit investors over the long term.
What are the top holdings in PBPH?
As of 2026-03-15, PBPH's top holdings are concentrated in leading global pharmaceutical companies. The top three holdings are Eli Lilly and Co (13.85%), Johnson & Johnson (9.35%), and AbbVie Inc (6.33%). These companies represent a significant portion of the fund's assets, reflecting PBPH's strategy of focusing on the largest players in the pharmaceutical industry. Investors should be aware of the concentration risk associated with these top holdings.
Is PBPH a good long-term investment?
Whether PBPH is a suitable long-term investment depends on an individual investor's specific financial goals, risk tolerance, and investment horizon. PBPH offers targeted exposure to the global pharmaceutical industry, which may appeal to investors seeking growth in this sector. However, the fund's concentrated portfolio and sector-specific risks should be carefully considered. With a beta of 0.00, PBPH has historically exhibited low volatility relative to the broader market. Investors should conduct thorough research and consult with a financial advisor before making any investment decisions. Past performance does not guarantee future results.
How does PBPH compare to similar ETFs?
PBPH distinguishes itself through its highly concentrated strategy of holding only the 10 largest global pharmaceutical companies. This contrasts with broader healthcare ETFs that may include a wider range of companies across various healthcare sub-sectors. When comparing PBPH to similar ETFs, factors may be worth researching such as expense ratios, AUM, and investment strategies. Some ETFs may offer broader diversification within the healthcare sector, while others may focus on specific sub-sectors or market segments. The best choice depends on an investor's specific investment objectives and risk tolerance.
Does PBPH pay dividends?
According to the provided data, PBPH has a dividend yield of 0.00% as of 2026-03-15. This indicates that the fund does not currently distribute dividends to its shareholders. Investors seeking income-generating investments may need to consider alternative ETFs with higher dividend yields. However, PBPH's focus on capital appreciation within the pharmaceutical sector may still be attractive to investors with different investment goals.